ArticleAnnals of cardiothoracic surgery2016
The role of adjuvant chemotherapy following resection of early stage thymoma.
Article in Annals of cardiothoracic surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- The role of adjuvant chemotherapy in patients with thymoma and thymic carcinoma following surgery: a systematic literature review and meta-analysis.Journal of thoracic disease · 2025Article
- Surgical treatment strategies for invasive thymoma.Journal of thoracic disease · 2020Review
- Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors.International journal of molecular sciences · 2020Review
- Assessment of the prognostic role of neutrophil-to-lymphocyte ratio following complete resection of thymoma.Journal of cardiothoracic surgery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is a paucity of data regarding adjuvant chemotherapy for resected early stage thymoma. This systematic review was designed to investigate the effect of adjuvant chemotherapy on outcomes in patients with early stage thymomas.
methodsPubMed database was queried for studies containing information on adjuvant chemotherapy following surgery in patients with Masaoka stage I or II thymoma.
resultsEight retrospective observational studies were reviewed. The number of patients with stage I or II thymoma was not clearly reported in several studies. Five studies reported on 890 patients with stage I or II patients, including 140 patients (15.7%) who received adjuvant chemotherapy with or without radiotherapy. No study reported short-term mortality in patients undergoing adjuvant chemotherapy following thymectomy.
conclusionsAdjuvant chemotherapy following resection of early thymomas appears to be a safe approach with favorable short-term outcomes. However, long-term outcomes remain unclear. There is no strong evidence to support adjuvant chemotherapy following resection of early-stage thymoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.